Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Modulating IL-21-driven B cell responses in idiopathic inflammatory myopathies via inhibition of the JAK/STAT pathway

Fig. 5

Effects of tofacitinib on B cell differentiation from ASyS patients in a 12-day PBMC culture. PBMC were cultured with BAFF/CpG/IL-21, with or without tofacitinib, and DMSO was used as control. (A) Representative dot plots and analysis of the percentage of naive (CD27-IgD+), switched memory (SWM, CD27+IgD-), double negative (CD27-IgD-), non-switched memory (NSM, CD27+IgD+) cells. (B) Representative dot plots and analysis of the percentage of CD27+CD38+ plasmablasts (within CD19+CD20+ B cells) and of CD138+ PC (within CD3- cells). (C) Total levels of IgG, IgM and IgA detected by ELISA and (D) anti-Jo1 detected with ELiA. (E) Levels of CXCL10 and CXCL13 in supernatants measured by Luminex. ASyS: anti-synthetase syndrome. Tofa: tofacitinib (2.5 µM). Graphs show the mean, SD and individual values (*p < 0.05, **p < 0.01, n = 4 ASyS patients)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us